Capricor Therapeutics, Inc.

One-third of all the regenerative medicine advanced therapy (RMAT) designations granted by the US Food and Drug Administration’s Center for Biologics Evaluation and Research were awarded in fiscal yea

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

After succeeding in a Phase III trial, AB2 Bio has secured a licensing deal with Nippon Shinyaku for its autoimmune disease candidate, tadekinig alfa. The Switzerland-headquartered firm has granted ex

The team behind Biomedtracker at Citeline have scoured the late-stage pipeline for drugs producing pivotal clinical trial data and likely to undergo FDA review and/or launch during 2025. This reveals